Tennessee House Bill HB2457

Tennessee 2025-2026 Regular Session

• Introduced: 2/3/26
• Refer: 2/5/26

Caption

AN ACT to amend Tennessee Code Annotated, Title 4; Title 56 and Title 71, relative to the coverage of long-acting injectable drugs for the treatment or prevention of human immunodeficiency virus.

Impact

If enacted, HB2457 will create a framework that guarantees reimbursement for long-acting injectable HIV treatment and prevention drugs, placing a significant emphasis on making these health interventions widely available. The amendment underscores the critical role of pharmacies, physicians' offices, and clinics in delivering essential medical services, which could improve health outcomes for those requiring such treatments. The bill's implications extend to MCOs and PBMs, translating into potential changes in how they structure their reimbursement policies.

Summary

House Bill 2457 seeks to amend the Tennessee Code to improve access to long-acting injectable drugs specifically designed for the treatment and prevention of human immunodeficiency virus (HIV). The bill mandates that managed care organizations (MCOs) and pharmacy benefits managers (PBMs) must reimburse claims for these injectable drugs when administered in various health care settings. This legislative effort is part of a broader initiative to enhance health care responses to HIV in the state, ensuring that treatments are more accessible to patients in need.

Sentiment

The sentiment surrounding HB2457 is largely positive, especially among health advocates and organizations focused on HIV treatment. Supporters perceive the bill as a crucial step towards addressing the public health challenges associated with HIV. However, there may be some contention related to the implementation details and the potential financial implications for MCOs and PBMs, which could spark discussion about costs and sustainability.

Contention

Notable points of contention may arise concerning the operational challenges that MCOs and PBMs face in adapting to these new reimbursement requirements. There could be discussions about the financial impact on these organizations and their ability to manage costs while complying with the new mandates. Furthermore, stakeholders may debate the timing of the bill's effective date, which is set for July 1, 2026, considering whether this timeline provides adequate preparation for the involved parties.